The most common side effects of acarbose are gastrointestinal: flatulence, bloating, abdominal pain, and diarrhea. These symptoms are more frequent early in treatment and tend to fade as the body adjusts, but they are also the main reason people stop taking the drug. Beyond the gut, acarbose can cause dose-related elevations in liver enzymes and interacts with a handful of other medications in ways worth knowing about. The full picture is more encouraging than that list might suggest, though, particularly when it comes to cardiovascular safety.
Why Acarbose Causes So Much Gas
Acarbose works by slowing down carbohydrate digestion in the small intestine. It blocks the enzymes that break complex starches and sugars into glucose, which blunts the blood sugar spike that normally follows a meal. The trade-off is that undigested carbohydrate keeps moving downstream and arrives in the large intestine, where trillions of bacteria are happy to ferment it. That fermentation produces gas, along with short-chain fatty acids like acetate, propionate, and butyrate.1PubMed. Changes of fermentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon The gas is the source of the flatulence and bloating that nearly every acarbose user notices, and the abdominal pain that some experience alongside it.2PubMed. Effects of beano on the tolerability and pharmacodynamics of acarbose
This mechanism is not a sign that something has gone wrong. It is the drug doing exactly what it is designed to do. The more carbohydrate you eat, and the higher your dose, the more substrate reaches the colon and the more gas your gut bacteria produce. That direct relationship between diet, dose, and symptoms is actually useful, because it means you have levers to pull.
Digestive Symptoms Usually Improve Over Time
A large safety review pooling data from clinical trials found that the gastrointestinal side effects of acarbose were significantly more common than with placebo but occurred more often early in treatment and attenuated as the weeks went on.3PubMed. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus The likely explanation is that the bacterial population in the colon adapts. When a new, larger supply of fermentable starch arrives regularly, the microbial community shifts. Gas-producing pathways may become less dominant relative to pathways that generate short-chain fatty acids without as much bloating. The subjective experience for most people is that the first few weeks are the worst, and things settle down considerably by the second or third month.
This fade is real enough that guidelines and prescribing advice emphasize patience. The GI side effects of acarbose are described as mild to moderate, and continuing treatment through the initial adjustment period is generally recommended as long as symptoms are tolerable.4BioMed Central / Cardiovascular Diabetology. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
How to Keep the Discomfort Manageable
Three strategies consistently show up in clinical guidance for minimizing acarbose-related gut trouble:
- Start low, go slow: Prescribers typically begin with a low dose (often 25 mg with meals) and increase gradually over weeks. This gives the colon time to adapt before a full therapeutic dose arrives. Jumping straight to a high dose is a reliable recipe for misery.
- Watch carbohydrate intake: Because the GI effects track directly with how much undigested starch reaches the colon, a meal heavy in refined carbohydrates will produce more symptoms than a moderate, mixed meal. This is not about avoiding carbs entirely; it is about not overwhelming the system while you are still adjusting.
- Focused patient education: Understanding that the symptoms are expected, temporary, and manageable makes a real difference in whether people stick with the drug long enough to see the adjustment happen.
Slow titration, dietary guidance, and good patient education together can meaningfully reduce the burden of gastrointestinal side effects.5BMJ. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes In the large ACE trial, which enrolled more than 6,500 people, gastrointestinal problems were the most common reason for changing dose or stopping treatment, but the actual discontinuation rate attributable to gut issues was about 7% in the acarbose group versus 5% in the placebo group.6The Lancet Diabetes & Endocrinology. Acarbose for cardiovascular reduction in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial That gap is narrower than many people expect.
Liver Enzyme Elevations
Acarbose can raise liver enzyme levels in the blood, a signal that merits monitoring even though it rarely causes liver symptoms. In American clinical trials, about 4% of acarbose-treated patients showed elevated liver transaminases compared with roughly 1% of those on placebo.7PubMed. Safety profile of acarbose, an alpha-glucosidase inhibitor A systematic review and meta-analysis looking at the class of drugs acarbose belongs to found that the odds of large transaminase elevations (more than three times the upper limit of normal) were several-fold higher in patients taking these medications, and that higher doses appeared to carry more risk.8Scientific Reports. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis
Two reassuring points stand out. First, the enzyme elevations were typically asymptomatic, meaning people felt fine and the abnormality showed up only on blood work. Second, the elevations reversed after the drug was stopped. The dose-response pattern is the practical takeaway: patients on doses above 100 mg three times a day faced more hepatic risk than those on moderate doses. Your doctor will likely check liver enzymes periodically, especially if you are on a higher dose, and that monitoring is enough to catch a problem before it becomes significant.
Acarbose and Kidney Disease
Prescribing labels have historically warned against using acarbose in patients with severe kidney impairment, because the drug and its metabolites could theoretically accumulate when the kidneys are not filtering well. Real-world data has softened that concern. A large population-based cohort study of patients with stage 5 chronic kidney disease or end-stage renal disease found that acarbose use was not associated with an increased risk of liver injury in this group, despite the theoretical pharmacokinetic worries.9PubMed Central. Acarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort Study
A separate nationwide longitudinal study in patients with type 2 diabetes and end-stage renal disease went further, finding that greater acarbose exposure was associated with lower risks of liver injury, cardiovascular events, and death.10PubMed. Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study These are observational findings, so they cannot prove that acarbose itself is responsible for the protective signal. But they do suggest that the theoretical risk in kidney disease patients may have been overstated, and that acarbose could be a useful option for people with limited treatment choices due to renal impairment. Any decision to use acarbose in this setting should still involve close monitoring and discussion with a nephrologist.
Drug Interactions to Be Aware Of
Acarbose’s drug interaction profile is relatively short, but a few interactions matter in practice. It can affect the bioavailability of metformin, which is relevant because the two drugs are commonly prescribed together for type 2 diabetes. It also becomes less effective when taken alongside intestinal adsorbents (like activated charcoal) or digestive enzyme preparations, both of which interfere with the mechanism that makes acarbose work.11American Journal of Health-System Pharmacy. Acarbose: An α-glucosidase inhibitor
One interaction that catches people off guard involves the treatment of low blood sugar. If you are taking acarbose alongside insulin or a sulfonylurea and you experience hypoglycemia, you need to treat it with pure glucose (such as glucose tablets or gel) rather than ordinary table sugar or juice. Acarbose blocks the breakdown of sucrose and complex carbohydrates, so those foods will not raise your blood sugar fast enough when you need a quick correction. This is not dangerous if you know about it in advance, but it can be alarming if you do not.
Cardiovascular Safety and Potential Benefit
Early evidence suggested that acarbose might do more than manage blood sugar. The STOP-NIDDM trial, which studied people with impaired glucose tolerance (a pre-diabetic state), found that acarbose was associated with a roughly 50% reduction in cardiovascular events and a meaningful reduction in new cases of high blood pressure.12PubMed. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial A meta-analysis of seven long-term studies in people with type 2 diabetes found that acarbose significantly reduced the risk of heart attack and of cardiovascular events overall, while also improving triglyceride levels, body weight, and blood pressure.13European Heart Journal. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
The story got more complicated with the ACE trial, a much larger study of over 6,500 patients with coronary heart disease and impaired glucose tolerance in China. That trial found no significant difference between acarbose and placebo for a composite of major cardiovascular events over about five years of follow-up. Acarbose did significantly reduce the development of new diabetes in that study, but the cardiovascular benefit seen in STOP-NIDDM did not replicate.14The Lancet Diabetes & Endocrinology. Acarbose for cardiovascular reduction in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
The bottom line for cardiovascular safety is reassuring either way. Even the ACE trial showed no cardiovascular harm. Whether acarbose actively protects the heart remains debated, but it does not appear to hurt it, which is more than can be said for every diabetes drug on the market.
How Acarbose Compares to Miglitol
Acarbose is not the only alpha-glucosidase inhibitor available. Miglitol belongs to the same drug class and works through a similar mechanism, but its side effect profile is not identical. A head-to-head crossover study in healthy men found that acarbose produced more flatulence and abdominal bloating, while miglitol was more likely to cause soft stools. The researchers suggested that patients who struggle with gas and bloating on acarbose might do better switching to miglitol, while those who have diarrhea or loose stools might actually tolerate acarbose better.15Internal Medicine. Comparison of Adverse Gastrointestinal Effects of Acarbose and Miglitol in Healthy Men: A Crossover Study If gut side effects are driving you away from one of these drugs, it may be worth trying the other before abandoning the class entirely.
A Rare but Serious Complication
Pneumatosis cystoides intestinalis, a condition in which gas-filled cysts form in the wall of the intestine, has been reported in connection with acarbose use. It is rare enough that a literature review identified only 28 cases across both acarbose and a related drug, voglibose. Those cases typically involved older patients (median age 64) who had been on the medication for a prolonged period, often more than a year, and who had other health conditions like hypertension or autoimmune disease.16PubMed Central. Acarbose-Induced Pneumatosis Cystoides Intestinalis The condition is usually found incidentally on imaging and resolves after the drug is stopped. It is worth knowing about, not because it should scare you, but because a radiologist might flag it and your doctor should connect it to the medication rather than pursuing aggressive workups.
What Acarbose Does to Gut Bacteria
The flood of undigested starch into the colon does not just cause gas. It reshapes the microbial community living there. A randomized, double-blind crossover trial in people with prediabetes found that acarbose significantly increased bacteria known to produce short-chain fatty acids, including species of Faecalibacterium, Prevotella, and Lactobacillus.17PubMed Central. Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial Short-chain fatty acids, particularly butyrate, are broadly considered beneficial for colon health and may play roles in reducing inflammation and improving metabolic signaling.
This microbiome shift is increasingly seen as a feature rather than a bug. Some researchers in the longevity field have become interested in acarbose partly because of these prebiotic-like effects, not just the blood sugar lowering. It is an unusual position for a side effect to occupy: the same mechanism that makes you gassy is also feeding bacteria that might be protecting your gut lining. Whether the microbiome changes translate into meaningful clinical benefits beyond glucose control is still an open question, but the direction of the evidence is encouraging.
Tolerability in Healthy People Using Acarbose Off-Label
Acarbose has attracted attention outside of diabetes treatment, particularly among people interested in longevity and healthspan. Animal studies (in mice, specifically) have shown lifespan extension with acarbose, and some people without diabetes have started taking it intermittently to blunt post-meal glucose spikes. A small study in healthy individuals using acarbose around meals found that while participants did report flatulence, bloating, nausea, and abdominal pain, these symptoms were also reported during control periods without the drug. No statistically significant difference in tolerability was detected between the acarbose and control periods.18Translational Medicine of Aging. The efficacy and tolerability of intermittent prandial acarbose to reduce glucose spikes in healthy individuals
That finding does not mean acarbose has no side effects in healthy people. The study was small, and the subjective reports are hard to separate from the normal digestive variability that everyone experiences. What it does suggest is that intermittent, lower-dose use in people without diabetes may be more tolerable than the chronic higher-dose use typical in diabetes management. Anyone considering off-label acarbose should still be aware of the liver enzyme issue and the drug interactions described earlier, and should ideally have liver function monitored periodically regardless of the reason they are taking it.
The Iron and Anemia Signal
One underappreciated finding from early clinical trials was a small increase in anemia among acarbose-treated patients, roughly 1% above the rate seen in placebo groups.19PubMed. Safety profile of acarbose, an alpha-glucosidase inhibitor The mechanism is not entirely clear. One possibility is that altered carbohydrate absorption in the small intestine affects the absorption of iron or other nutrients, though this has not been conclusively demonstrated. For most people on acarbose, this is not clinically significant. But if you are already at risk for iron deficiency, such as from heavy menstrual periods, a vegetarian diet, or chronic kidney disease, it is a signal worth discussing with your doctor. Routine blood work will catch any meaningful drop in hemoglobin well before it becomes a problem.